New drug combo aims to shrink advanced prostate cancer before surgery
NCT ID NCT05873192
Summary
This study is testing whether adding a drug called talazoparib to standard hormone therapy (enzalutamide and ADT) is more effective at treating prostate cancer that has spread to nearby lymph nodes. The goal is to see if this combination can better control the cancer before patients undergo surgery to remove the prostate. Researchers will measure success by checking if cancer markers become undetectable after treatment and surgery, and by monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.